Intratumoral administration of CD1c (BDCA-1)⁺ and CD141 (BDCA-3)⁺ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial.

ABSTRACT:

Background

Intratumoral (IT) myeloid dendritic cells (myDCs) play a pivotal role in initiating antitumor immune responses and relicensing of anti-tumor cytotoxic T lymphocytes within the tumor microenvironment. Talimogene laherparepvec (T-VEC) induces immunogenic cell death, thereby providing maturation signals and enhancing the release of tumor antigens that can be captured and processed by CD1c (BDCA-1)⁺ / CD141 (BDCA-3)⁺ myDCs, in order to reinvigorate the cancer-immunity cycle.

Methods

In this phase I trial, patients with advanced melanoma who failed standard therapy were eligible for IT injections of ≥1 non-visceral metastases with T-VEC on day 1 followed by IT injection of CD1c (BDCA-1)⁺ myDCs +/- CD141 (BDCA-3)⁺ myDCs on day

SUBMITTER: Schwarze JK 

PROVIDER: S-EPMC9486335 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature